The effect of varenicline on heart rate variability in healthy smokers and nonsmokers

Autonomic Neuroscience: Basic and Clinical

Volumn 164, Issue 1-2, 2011, Pages 82-86

  Ari, Hasan ^a   Celiloǧlu, Nuran ^a   Ari, Selma ^a   Coşar, Selvi ^a   Doganay, Kübra ^a   Bozat, Tahsin ^a  

^a Bursa Postgraduate Hospital   (Turkey)

Author keywords

Autonomic nervous system; Cardiac; Smoking cessation; Varenicline

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; EXERCISE; FEMALE; HAND GRIP; HEART PALPITATION; HEART RATE; HEART RATE VARIABILITY; HUMAN; HYPOTENSION; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; STATISTICAL SIGNIFICANCE; SUPINE POSITION; SWEATING;

ADULT; ARRHYTHMIAS, CARDIAC; BENZAZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; NICOTINIC AGONISTS; PLACEBOS; QUINOXALINES; SMOKING; YOUNG ADULT;

EID: 80052269493     PISSN: 15660702     EISSN: 18727484     Source Type: Journal    
DOI: 10.1016/j.autneu.2011.05.005     Document Type: Article

References (27)

1. Aberger K., Chitravanshi V.C., Sapru H.N. Cardiovascular responses to microinjections of nicotine into the caudal ventrolateral medulla of the rat. Brain Res. 2001, 892:138-146.
2. Benowitz N.L., Porchet H., Sheiner L., Jacob P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin. Pharmacol. Ther. 1988, 44:23-28.
3. Bernston G.G., Bigger J.T., Eckberg D.L., Grossman P., Kaufmann P.G., Malik M., Nagaraja H.N., Porges S.W., Saul J.P., Stone P.H., van der Molen M.W. Heart rate variability: origin, methods, and interpretive caveats. Psychophysiology 1997, 34:623-648.
4. Centers for Disease Control and Prevention, US Department of Health and Human Services The health consequences of smoking: a report of the SurgeonGeneral Available at:, Accessed January 30. http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2004/chapters.htm.
5. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Huang J., Sands S.B., Davis T.I., Lebel L.A., Fox C.B., Shrikhande A., Heym J.H., Schaeffer E., Rollema H., Lu Y., Mansbach R.S., Chambers L.K., Rovetti C.C., Schulz D.W., Tingley F.D., O'Neill B.T. Varenicline: an alpha-4 beta-2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 2005, 48:3474-3477.
6. Critchley J.A., Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003, 290:86-97.
7. Dhar S., Nagy F., McIntosh J.M., Sapru H.N. Receptor subtypes mediating depressor responses to microinjections of nicotine into medial NTS of the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279:R132-R140.
8. Di Angelantonio S., Matteoni C., Fabbretti E., Nistri A. Molecular biology and electrophysiology of neuronal nicotinic receptors of rat chromaffin cells. Eur. J. Neurosci. 2003, 17:2313-2322.
9. Faessel H.M., Smith Bill J., Gibbs Megan A., Gobey Jason S., Clark David J., Burstein Aaron H. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J. Clin. Pharmacol. 2006, 46:991-998.
10. Fiore M.C., Jae'n C.R., Baker T.B., Bailey W.C., Benowitz N.L., Curry S.J., Dorfman S.F., Froelicher E.S., Goldstein M.G., Healton C.G., Henderson P.N., Heyman R.B., Koh H.K., Kottke T.E., Lando H.A., Mecklenburg R.E., Mermelstein R.J., Mullen P.D., Orleans C.T., Robinson L., Stitzer M.L., Tommasello A.C., Villejo L., Wewers M.E. Treating tobacco use and dependence: 2008 update. clinical practice guideline: U.S. Department of Health and Human Services, Public Health Service Available at, Accessed March 12. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid_hstat2.chapter.28163.
11. Hays J.T., Ebbert J.O. Varenicline for tobacco dependence. N. Engl. J. Med. 2008, 359:2018-2024.
12. Ji S., Tosaka T., Whitfield B.H., Katchman A.N., Kandil A., Knollmann B.C., Ebert S.N. Differential rate responses to nicotine in rat heart: evidence for two classes of nicotinic receptors. J. Pharmacol. Exp. Ther. 2002, 301:893-899.
13. Jimenez-Ruiz C., Berlin I., Hering T. Varenicline A Novel Pharmacotherapy for Smoking Cessation. Drugs 2009, 69:1319-1338.
14. Khurana R.K., Setty A. The value of the isometric handgrip test-studies in various autonomic disorders. Clin. Auton. Res. 1996, 6(4):211-218.
15. Kingwell B.A., Thompson J.M., Kaye D.M., McPherson G.A., Jennings G.L., Esler M.D. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation 1994, 90:234-240.
16. Kleiger R.E., Miller J.P., Bigger J.T., Moss A.J. Multicenter post infarction myocardial infarction research group: decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am. J. Cardiol. 1987, 59:256-262.
17. Minami J., Ishimitsu T., Matsuoka H. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension 1999, 33:586-590.
18. Perkins K.A., Grobe J.E., Fonte C., Goettler J., Caggiula A.R., Reynolds W.A., Stiller R.L., Scierka A., Jacob R.G. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J. Pharmacol. Exp. Ther. 1994, 270:628-638.
19. Perkins K.A., Gerlach D., Broge M., Grobe J.E., Sanders M., Fonte C., Vender J., Cherry C., Wilson A. Dissociation of nicotine tolerance from tobacco dependence in humans. J. Pharmacol. Exp. Ther. 2001, 296:849-856.
20. Rigotti N.A., Pipe A.L., Benowitz N.L., Arteaga C., Garza D., Tonstad S. Efficacyand safety of varenicline for smoking cessation in patients withcardiovascular disease: a randomized trial. Circulation 2010, 121:221-229.
21. Rowell L.B. Human cardiovascular control 1993, Oxford University Press, Oxford, UK.
22. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., Mosca L., Pasternak R.C., Pearson T., Pfeffer M.A., Taubert K.A. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
23. Srivastava E.D., Russell M.A.H., Feyerabend C., Masterson J.G., Rhodes J. Sensitivity and tolerance to nicotine in smokers and nonsmokers. Psychopharmacology 1991, 105:63-68.
24. Task force of European Society of Cardiology and the North American Society of Pacing and Electrophysiology Heart rate variability, standards of measurement, physiological interpretation and clinical use. Circulation 1996, 93:1043-1065.
25. Tsuji H., Venditti F.J., Manders E.S., Evans J.C., Larson M.G., Feldman C.L., Levy D. Reduced heart rate variability and mortality risk in elderly cohort. Circulation 1994, 90:878-883.
26. Watanabe N., Reece J., Polus B.I. Effects of body position on autonomic regulation of cardiovascular function in young, healthy adults. Chiropr. Osteopat. 2007, 15:19.
27. Yotsukura M., Koide Y., Fujii K., Tomono Y., Katayama A., Ando H., Suzuki J., Ishikawa K. Heart rate variability during the first month of smoking cessation. Am. Heart J. 1998, 135(6pt 1):1004-1009.